/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that.
Patients with early-stage breast cancer who have an elevated risk of having tumour recurrence now have the option to take a course of radiotherapy following breast conservation surgery that is only three weeks long, half the time of conventional radiotherapy treatment.
Three-week course of radiation safe and effective for patients with early-stage breast cancer and elevated risk of recurrence miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.